Adhering to NPPA guidelines, the product is priced at Rs 29,600
Tagged as a breakthrough innovation for patients with clogged arteries, the Shanghai-based medical technology company MicroPort Scientific Corporation, launched its ‘Firehawk’ target eluting stent in India.
Announcing the launch of Firehawk stent and MicroPort’s venture into India, Jonathan Chen, Senior Vice President of International Operations and Investor Relations, said, “MicroPort is becoming a major global player in the medical devices industry. We hope to offer better solution of interventional therapies for the Indian market and bring patients a whole generation of affordable medical technologies to improve the lives for Indian patients.”
According to MicroPort Scientific Corporation, the new product adheres to NPPA guidelines and costs Rs 29,600. Firehawk stent was recently used in a Mumbai hospital.
Informing on how Firehawk is unique and different from other premium biodegradable stents, which is available in the Indian markets and offered by global giants like Boston Scientific, Medtronics, Chen said, “Firehawk is a third generation target eluting stent and its design is driven by a desire to minimise stent thrombosis. Using the reservoir technology, Firehawk helps in combating stent thrombosis as it minimises vessel wall inflammation through a reduction in the spatial and temporal interaction between polymer, drug and vessel wall. Target Eluting Stent technology allows Firehawk to achieve the same clinical efficacy as other market leading drug eluting stent with only 1/3rd dosage of the drug .”
Chen further said that MicroPort has been active in expanding its business globally and is eyeing a much bigger market for India other than stents.
Talking about Indian operations, Riyaz Desai, Managing Director India, MicroPort Scientific Corporation said, “We are here not only at an opportune time, but I genuinely feel that Indian medical ecosystem is maturing and forcing manufacturers to provide the best in class medical care at affordable prices.”
- Advertisement -
Comments are closed.